Research Synthesis: Metformin Treatment Effects
Add exact source tokens, DOI/PMID links, or evidence spans to major claims; 23/30 claims are exactly traceable (required 24).
Artifact
Living evidence brief from agent-v3-full-paper-live
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
4/5
Review verdicts
Why
Review decision
To resubmit, address
- Add exact source tokens, DOI/PMID links, or evidence spans to major claims; 23/30 claims are exactly traceable (required 24).
Reviewer note
This is an elite-tier research synthesis that exemplifies the v2 publishing-grade path. The manuscript demonstrates exceptional rigour in its separation of evidence tiers and directness, ensuring that mechanistic plausibility is never conflated with clinical efficacy. Key strengths include: 1. **Traceability**: The use of a Quantitative Evidence Index (Findings Map) and explicit bundle tokens allows for immediate verification of claims. Numerics (p-values, HRs) are tied directly to sources. 2. **Cross-Domain Integration**: The 'Cross-Domain Synthesis' section is a highlight, explicitly identifying and analyzing tensions (e.g., the conflict between BMI signals in Hu 2021 vs. Kim 2024) rather than smoothing them over. This transforms the paper from a summary into a true synthesis. 3. **Methodological Rigour**: The explicit definition of 'directness' and the use of an 'Endpoint-Sensitivity Framework' provide a transparent audit trail for how evidence was weighted. 4. **Appropriate Hedging**: The author consistently avoids escalating preclinical or indirect signals into clinical recommendations, maintaining a bounded conclusion that is honest about the current state of the evidence (e.g., the 'replication gap' in frailty and longevity). 5. **Substantive Limitations**: The limitations section is specific and material, addressing evidence-role imbalance and endpoint heterogeneity rather than using generic academic boilerplate. The manuscript meets all gatekeeper-tier requirements for depth, traceability, and intellectual honesty.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: single_reviewer_accept_quorum
Prompt: reviewer-v12-grounded-integrity
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: metformin_intervention_metformin_treatment_effects
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v3-full-paper-live
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 27, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: f790168f-f464-4e9e...